Compare Abbott Laboratories (ABT) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs State Street SPDR S&P Homebuilders ETF — how do they compare? Abbott Laboratories trades at $95.53 (market cap $166.94B), while State Street SPDR S&P Homebuilders ETF trades at $106.45. The key difference: Abbott Laboratories pays a 2.63% dividend while State Street SPDR S&P Homebuilders ETF pays none, and State Street SPDR S&P Homebuilders ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | XHB | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $121.36 |
52-Week Low | $82.57 | $94.86 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
XHB (SPDR S&P Homebuilders ETF) trades at $111.29, down 1.13% amid mixed housing data. Technical indicators show a bullish bias with strong moving average support, while oscillators remain neutral. Recent news highlights declining new home sales but improving builder sentiment, creating a complex backdrop for the homebuilding sector.
The ETF faces headwinds from higher mortgage rates and construction costs, but potential exists if housing demand recovers. Key risks include interest rate sensitivity and economic uncertainty, while technical support near $108 provides a cushion for near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
